Want to create an interactive transcript for this episode?
Podcast: Decera Clinical Education Infectious Disease Podcast
Episode: Investigational PPAR-delta Agonist for PBC Treatment and Race-Based Considerations for PBC Diagnosis: Conference Coverage of AASLD
Description: During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including:Â A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored r...